

# Contents

CONTENTS

CONTENTS

<b>1 Introduction to Basic Immunology and Techniques</b>	<b>1</b>	3.5 Fetal genotyping	76
<i>Neil D. Avent</i>		3.6 Clinical management—obstetrics	77
Introduction	1	3.7 Concluding comments	80
1.1 Basic immunology and techniques	4	<i>Chapter summary</i>	80
1.2 Antibody structure	6	<i>Further reading</i>	80
1.3 Antibody function	8	<b>4 Clinical Use of Blood Components</b>	<b>82</b>
1.4 Antigen–antibody reactions	9	<i>Lionel Mohabir</i>	
1.5 Antibody-mediated red cell destruction	10	Introduction	82
1.6 <i>In vitro</i> detection of antigen–antibody reactions	13	4.1 Structure and function of blood	83
1.7 Techniques	17	4.2 Normal physiological response to anaemia and/or bleeding	83
<i>Chapter summary</i>	18	4.3 Blood coagulation	84
<b>2 Human Blood Group Antigens</b>	<b>19</b>	4.4 Blood components available and their appropriate use	86
<i>Neil D. Avent</i>		4.5 Blood products	92
Introduction	19	4.6 Special requirements	93
2.1 Human polymorphism and evolution	20	4.7 Plasma fractionation	93
2.2 The erythrocyte membrane	23	4.8 Decision making, who needs a transfusion, risks and benefits	98
2.3 Blood group systems dependent on carbohydrate structures	27	4.9 Alternatives to donor blood	100
2.4 Blood group systems dependent on protein structures	33	4.10 Case history examples	105
2.5 Non-polymorphic erythrocyte membrane proteins	57	<i>Chapter summary</i>	106
2.6 Blood group genotyping (BGG)	58	<i>Further reading</i>	107
<i>Chapter summary</i>	60	<b>5 Microbiological Testing of Blood Donations</b>	<b>108</b>
<i>Further reading</i>	61	<i>Catherine Hyland, John Barbara, and Lionel Mohabir</i>	
<b>3 Haemolytic Disease of the Fetus and Newborn</b>	<b>62</b>	Introduction	108
<i>Neil D. Avent</i>		5.1 Requirements for microbiological testing of blood donations	109
Introduction	62	5.2 The virus life cycle: basic biology	110
3.1 Fetal alloimmunization	63	5.3 Epidemiology for hepatitis B and C and for HIV (AIDS)	111
3.2 Clinical management—laboratory investigations	69	5.4 Screening strategy for mandatory viral tests	119
3.3 Prophylactic anti-D	72		
3.4 Neonatal alloimmune thrombocytopenia (NAITP)	76		

5.5	Testing strategy to protect immunocompromised patients	125	7.6	Adverse effects of transfusion	195
5.6	Bacterial tests for products stored at room temperature	126	7.7	Monitoring the patient during transfusion	199
5.7	Emerging issues for blood safety	129	7.8	Investigation of transfusion reactions	200
5.8	Insect/animal-borne pathogens	130	7.9	Haemovigilance in the UK	203
5.9	Arthropod (insect)-borne viruses, i.e. ARBO viruses	132		<i>Chapter summary</i>	207
5.10	Transmissible spongiform encephalitis, prions, and variant Creutzfeldt-Jakob disease	134		<i>Further reading</i>	207
5.11	Quality control and blood safety	136	<b>8 Immune-Mediated Red Cell Destruction</b>		<b>209</b>
5.12	Strategies for the future and conclusion	138		<i>Malcolm Needs</i>	
	<i>Chapter summary</i>	138		Introduction	209
	<i>Further reading</i>	139	8.1	What is immune (antibody-mediated) red cell destruction?	210
<b>6 Human Platelet Antigens (HPA) and Human Neutrophil Antigens (HNA) and Their Clinical Significance</b>		<b>141</b>	8.2	Clinical significance of red cell antibodies	212
	<i>Geoff Lucas</i>		8.3	Haemolytic transfusion reactions	215
	Introduction	142	8.4	Autoimmune haemolytic anaemias (AIHA)	218
6.1	Overview of platelet and granulocyte antigens	142	8.5	Haemolysis post-transplantation of bone marrow/stem cell transplant	225
6.2	Human platelet antigens (HPA)	144	8.6	Haemolysis post-solid organ transplant and hyperacute rejection	226
6.3	Human neutrophil antigens (HNA)	151	8.7	Haemolytic disease of the fetus and newborn (HDFN)	227
6.4	Antibody detection	155		<i>Chapter summary</i>	227
6.5	Clinical significance of HPA alloantibodies	165		<i>Further reading</i>	227
6.6	Clinical significance of HNA antibodies	174	<b>9 Human Leucocyte Antigens (HLA) and Their Clinical Significance</b>		<b>229</b>
	<i>Chapter summary</i>	178		<i>Neil D. Avent</i>	
	<i>Further reading</i>	179		Introduction	229
	<i>Discussion questions</i>	180	9.1	A brief history of transplantation	230
<b>7 Compatibility Testing and Adverse Effects</b>		<b>181</b>	9.2	Human leucocyte antigens	231
	<i>Malcolm Needs</i>		9.3	The detection and definition of human leucocyte antigens, alleles, and antibodies	237
	Introduction	181	9.4	Clinical significance of human leucocyte antigens in transplantation	242
7.1	Compatibility testing (serological and non-serological)	182	9.5	Clinical significance of human leucocyte antigens in transfusion	249
7.2	Selection of plasma products	192	9.6	Immunosuppression	253
7.3	Selection of cellular components	193	9.7	Xenotransplantation	255
7.4	Visual inspection and labelling of the units	194		<i>Chapter summary</i>	257
7.5	Traceability of blood components	195		<i>Further reading</i>	258
				<i>Discussion questions</i>	258

<b>10 Haematopoietic Stem Cell Transplantation and Stem Cell Plasticity</b>	<b>259</b>		
<i>Ruth Morse and Saeed Kabrah</i>			
Introduction	259		
10.1 Stem cells	260		
10.2 The bone marrow microenvironment	262		
10.3 Sources and collection of haematopoietic SCs	263		
10.4 Stem cell transplantation	272		
10.5 Novel approaches to personalized medicine and stem cell plasticity	278		
10.6 Concluding remarks	285		
<i>Chapter summary</i>	285		
<i>Further reading</i>	286		
<b>11 Tissue Banking</b>	<b>287</b>		
<i>Richard Lomas, Neil D. Avent, and Vehid Salih</i>			
Introduction	287		
11.1 Types of graft	288		
11.2 Which tissues are banked and how are they used?	289		
11.3 How are donors selected, screened, and consented?	291		
11.4 How are tissues retrieved?	294		
11.5 Tissue processing and preservation	298		
11.6 Storage and distribution	305		
11.7 The future—regenerative medicine	310		
<i>Chapter summary</i>	312		
<i>Further reading</i>	313		
<b>12 Quality Issues</b>	<b>315</b>		
<i>Joan Jones</i>			
Introduction	315		
12.1 Evolution of quality	316		
12.2 Quality management systems	318		
12.3 Blood safety and quality regulations	322		
12.4 The <i>In Vitro</i> Diagnostic Medical Devices Directive	324		
12.5 Clinical laboratory accreditation	324		
12.6 The Blood Stocks Management Scheme	325		
12.7 Other legislation and regulatory bodies	326		
12.8 Guidelines	327		
12.9 Haemovigilance	327		
<i>Chapter summary</i>	328		
<i>Further reading</i>	328		
Glossary	329		
Abbreviations	335		
Index	339		